ASCO 2018: Next-Generation Sequencing—Is It Right for Every Patient?
Chicago, IL (UroToday.com) In the era of precision oncology, next-generation sequencing (NGS) can play a critical role in the determination of risk for genetic disease, and in patients with cancer, this technology may also inform on treatment. Assisted by the decreasing cost of sequencing DNA, numerous companies are developing NGS diagnostics to help complement patient care.
ASCO 2018: Challenges of Perioperative Systemic Therapy of Localized Urothelial Cancer
Chicago, IL (UroToday.com) Dr. Aragon-Ching started off this multi-disciplinary session on the management of bladder cancer. She, and the two other speakers, addressed 3 specific cases, highlighted below, in an effort to make their points. The 3 cases were:
ASCO 2018: Personalized Care in the Management of Kidney Cancer
Chicago, IL (UroToday.com) Renal cell carcinoma is the most common form of kidney cancer, with approximately 63,000 new cases and 14,000 deaths in the United States in 2017. Therapy for metastatic clear cell RCC (mRCC) has changed dramatically over the past decade as has the overall median survival of patients – in the cytokine era, median overall survival was about 12 months. Now, in the front line VEGF era, median overall survival has more than doubled to 26 months1.
ASCO 2018: Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer
Chicago, IL (UroToday.com) Gary Steinberg, MD was the second speaker in this multi-disciplinary session on the management of bladder cancer. The speakers addressed 3 specific cases, highlighted below, in an effort to make their points.
ASCO 2018: Geriatric Assessment Improves Communication Between Oncologists and Older Patients
Truckee, CA (UroToday.com) -- A federally funded randomized study demonstrated that the use of geriatric assessment in routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns as well as patient satisfaction with the communication.
ASCO 2018: Abiraterone May Be More Effective in Black Men with Advanced Prostate Cancer than in White Men
Truckee, CA (UroToday.com) -- In a prospective clinical trial of 100 men with metastatic castration-resistant prostate cancer, the response to the hormone treatment abiraterone (Zytiga®) was greater and longer lasting in black men than in white men. Black men were more likely to have a decline in prostate-serum antigen (PSA) -- a sign of prostate cancer response -- and had a 5-month longer median time to PSA worsening than white men (16.6 vs. 11.5 months).
ASCO 2018: Black Men with Advanced Prostate Cancer Treated with Chemotherapy May Have Equal or Better Survival than White Men
Truckee, CA (UroToday.com) -- An analysis of pooled data from nine randomized phase III trials of more than 8,000 men with advanced prostate cancer who received chemotherapy shows chances of survival are as good for black men as white men.